1. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients
- Author
-
Kalim, Sahir, Clish, Clary B, Wenger, Julia, Elmariah, Sammy, Yeh, Robert W, Deferio, Joseph J, Pierce, Kerry, Deik, Amy, Gerszten, Robert E, Thadhani, Ravi, and Rhee, Eugene P
- Subjects
Male ,Time Factors ,Kidney Disease ,Cardiorespiratory Medicine and Haematology ,Cardiovascular ,Mass Spectrometry ,Kidney Failure ,Renal Dialysis ,Risk Factors ,cardiovascular disease ,Clinical Research ,Carnitine ,Odds Ratio ,80 and over ,Humans ,Metabolomics ,Prospective Studies ,Chronic ,Uremia ,Aged ,Chromatography ,Liquid ,Chi-Square Distribution ,Middle Aged ,mortality ,Treatment Outcome ,Logistic Models ,Good Health and Well Being ,Cardiovascular Diseases ,Case-Control Studies ,Multivariate Analysis ,dialysis ,Female ,metabolism ,Biomarkers - Abstract
BackgroundThe marked excess in cardiovascular mortality that results from uremia remains poorly understood.Methods and resultsIn 2 independent, nested case-control studies, we applied liquid chromatography-mass spectrometry-based metabolite profiling to plasma obtained from participants of a large cohort of incident hemodialysis patients. First, 100 individuals who died of a cardiovascular cause within 1 year of initiating hemodialysis (cases) were randomly selected along with 100 individuals who survived for at least 1 year (controls), matched for age, sex, and race. Four highly intercorrelated long-chain acylcarnitines achieved the significance threshold adjusted for multiple testing (P
- Published
- 2013